Company announcement -- No. 56 / 2026
Zealand Pharma Announces Financial Results for the First Nine Months of 2026
Advancing at pace towards Metabolic Frontier 2030: petrelintide in Phase 3, survodutide moving towards regulatory filings, positive CHMP opinion for Zeydovio(TM) , and new modalities for next wave
-- Announced positive topline results from Phase 2 ZUPREME-2 trial with
petrelintide and initiated a registrational Phase 3 program, marking a
defining step toward establishing petrelintide as a future first-choice
therapy for people living with overweight or obesity.
-- Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-2
and SYNCHRONIZETM-CVOT trials with survodutide, demonstrating clinically
meaningful weight loss and improvements in glycemic control in people
with overweight or obesity and type 2 diabetes and a favorable
cardiovascular safety profile compared to placebo, and is moving forward
with global regulatory submissions in obesity in 2027.
-- Received positive CHMP opinion for ZeydovioTM (glepaglutide), the first
major advancement in short bowel syndrome treatment in Europe in over a
decade.
-- Opened new research hub in Cambridge, Massachusetts, and entered a
collaboration and license agreement with Generate Biomedicines to develop
AI-engineered protein therapeutics for metabolic diseases, broadening
Zealand Pharma's modality capabilities.
Copenhagen, Denmark, November 12, 2026 -- Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, today announced the interim report for the nine months ended September 30, 2026, and provided a corporate update.
Executing on Metabolic Frontier 2030
Adam Steensberg, President and Chief Executive Officer at Zealand Pharma said:
"This quarter, we made progress on every commitment in our Metabolic Frontier 2030 strategy. With positive ZUPREME-2 results and Phase 3 initiations, petrelintide moves closer to offering a differentiated treatment option and weight management experience. Boehringer Ingelheim finalized the extensive Phase 3 program with survodutide in obesity, reinforcing its strong metabolic profile and demonstrating preferential visceral and liver fat reductions while preserving muscle mass. We also progressed our novel Kv1.3 ion channel blocker and received a positive CHMP opinion for glepaglutide in short bowel syndrome.
At the same time, we are building what comes next. Our new Cambridge research hub and collaboration with Generate Biomedicines expand what we can discover and develop. By combining advanced modelling and AI-driven design with our deep metabolic health expertise, we are building a platform to move faster from idea to clinic and deliver 10 clinical programs by 2030."
Key financial results for Q3 2026 year-to-date
DKK million Q3-26 YTD Q3-26 YTD
---------------------- --------- ---------
Revenue 4,529 9,146
---------------------- --------- ---------
Operating expenses,
excl. OOI(1) -1,893 -1,479
---------------------- --------- ---------
Operating expenses(1) -1,262 -1,675
---------------------- --------- ---------
Operating profit 3,267 7,470
---------------------- --------- ---------
Net financial items 343 -62
---------------------- --------- ---------
Profit for the period 3,469 6,834
---------------------- --------- ---------
Sep-30, Dec-31,
DKK million 2026 2025
----------------- ------- -------
Cash position(2) 13,509 15,109
----------------- ------- -------
Notes:
1. Operating expenses consist of R&D, S&M, G&A and Other operating items (OOI).
2. Cash position includes cash, cash equivalents and marketable securities.
Q3 2026 Highlights and Recent Developments
Obesity
-- Petrelintide, amylin analog. Zealand Pharma reached a key milestone with
the initiation of the global Phase 3 registrational program, together
with Roche, to address important unmet medical needs in chronic weight
management. The program consists of three registrational trials and is
expected to enroll approximately 7,000 participants in total.
-- Petrelintide, amylin analog. The company reported positive topline
results from the Phase 2 ZUPREME-2 trial in people with overweight or
obesity and type 2 diabetes. Petrelintide delivered up to 9.2% weight
loss at week 28 and clinically meaningful HbA1c reductions of up to 0.65%
from a mean HbA1c at baseline of 7.7% (specified from 8.0% in original
company announcement). Safety and tolerability profile of petrelintide
was consistent with that seen in the Phase 2 ZUPREME-1 trial.
-- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim
presented results from the SYNCHRONIZETM-CVOT Phase 3 trial in people
living overweight or obesity with established cardiovascular disease
(CVD), chronic kidney disease, and/or at least two-weight related
complications or risk factors for CVD. As the first glucagon/GLP-1 dual
agonist, survodutide demonstrated a favorable cardiovascular safety
profile compared to placebo alongside significant cardiometabolic
benefits.
-- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim
presented results from the SYNCHRONIZETM-2 Phase 3 trial in people living
with overweight or obesity and type 2 diabetes. The trial met its primary
endpoints and showed up to 13.1% body weight reduction in a population in
which weight loss is typically more challenging along with improvements
in key markers of cardiometabolic health, including clinically meaningful
reductions in HbA1c and waist circumference.
-- Survodutide, glucagon/GLP-1 receptor dual agonist. Boehringer Ingelheim
expanded the development program for survodutide with the initiation of a
Phase 3 trial in people with type 2 diabetes and planned initiation of
three Phase 3b trials to address key unmet needs in people living with
obesity and real-world care.
-- ZP6590, GIP receptor agonist. Zealand Pharma initiated a first-in-human
Phase 1 clinical trial with ZP6590.
Chronic inflammation
-- ZP9830, Kv1.3 Ion Channel Blocker. Zealand Pharma initiated a Phase 1b
trial with efficacy endpoints, investigating ZP9830 in people with
psoriasis.
-- ZP9830, Kv1.3 Ion Channel Blocker. Zealand Pharma reported positive
topline data from the MAD part of the Phase 1a clinical trial. Multiple
doses of ZP9830 were well tolerated with no serious or severe adverse
events or dose-limiting safety findings observed. Pharmacokinetics
parameters support continued development of ZP9830 in trials of longer
duration.
Rare diseases
-- Glepaglutide in SBS. Zealand Pharma announced that the CHMP of the
European Medicines Agency (EMA) has recommended the approval of
ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome
(SBS).
Corporate
-- Zealand Pharma entered into a collaboration and license agreement with
Generate Biomedicines to develop protein therapeutics, broadening Zealand
Pharma's modality capabilities and opening new approaches for
polypharmacology for innovative therapeutics. The collaboration will
combine Zealand Pharma's metabolic health expertise with The Generate
Platform, which integrates generative AI with high-throughput
experimental validation.
-- Zealand Pharma announced opening of its new research hub in Cambridge,
Massachusetts. The 53,600 RSF (approximately 5,000 m2) site expands the
company's research capabilities beyond its core peptide expertise into
hybrid modalities, including biologics such as antibody peptide
conjugates. The platform will be built around automation and advanced
modeling techniques to accelerate medicine creation.
-- Zealand Pharma completed the share buy-back program, initiated on May 7,
2026. During the program, a total of 4,408,500 shares were repurchased at
a total gross value of DKK 1,300 million.
-- Zealand Pharma entered into a USD 100 million royalty purchase and sale
agreement with Royalty Pharma for rusfertide.
Upcoming events in 2026
Obesity
-- Petrelintide/enicepatide (CT-388), amylin+GLP-1/GIP fixed-dose
combination. Zealand Pharma and Roche expect to initiate the Phase 2
ZYNERGY trial in people with overweight or obesity in Q4 2026.
Rare diseases
-- Glepaglutide in SBS. Zealand Pharma expects a final decision on the EU
Marketing Authorization Application in Q4 2026. In parallel, the company
is engaging in partnership discussions for future commercialization of
glepaglutide for SBS.
-- Dasiglucagon in CHI. In Q4 2026, Zealand Pharma expects to resubmit the
New Drug Application (NDA) for congenital hyperinsulinism (CHI) to the
U.S. FDA. The submission will encompass both the three weeks use of
dasiglucagon (Part 1 of the original NDA) as well as the use beyond three
weeks (Part 2 of the original NDA).
Financial guidance for 2026
Comments